Agios Pharmaceuticals, Inc. (AGIO)
27.20
+0.22
(+0.82%)
USD |
NASDAQ |
May 07, 10:29
Agios Pharmaceuticals Cash from Investing (Quarterly) : 141.31M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Catalyst Pharmaceuticals, Inc. | -0.032M |
| Eli Lilly & Co. | -3.916B |
| Apellis Pharmaceuticals, Inc. | -0.108M |
| Alnylam Pharmaceuticals, Inc. | -25.54M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -118.92M |
| Cash from Financing (Quarterly) | 2.078M |
| Free Cash Flow | -384.73M |
| Free Cash Flow Per Share (Quarterly) | -2.036 |
| Free Cash Flow to Equity (Quarterly) | -115.23M |
| Free Cash Flow to Firm (Quarterly) | -119.69M |
| Free Cash Flow Yield | -24.26% |